TAD3 Antibody

What is TDRD3 and why is it significant in molecular biology research?

TDRD3 functions as a scaffolding protein that specifically recognizes and binds dimethylarginine-containing proteins. It plays dual roles depending on cellular localization: in the nucleus, it acts as a coactivator by recognizing and binding asymmetric dimethylation on core histone tails associated with transcriptional activation (H3R17me2a and H4R3me2a); in the cytoplasm, it serves as an antiviral factor participating in stress granule assembly together with G3BP1 . TDRD3's involvement in both epigenetic regulation and RNA metabolism makes it a significant target for studies exploring gene expression control mechanisms.

What types of TDRD3 antibodies are available for research applications?

The primary types of TDRD3 antibodies available include rabbit polyclonal antibodies targeting different epitopes of the protein. For example, commercial antibodies like ab251970 target recombinant fragments within human TDRD3 amino acids 300-450, while others like ab95879 target synthetic peptides corresponding to the C-terminal region (aa 600 to C-terminus) . Both monoclonal (mAB) and polyclonal (pAb) antibodies are available, with varying specificities and applications as indicated in validation studies from resources like The Human Protein Atlas .

How can I confirm the specificity of my TDRD3 antibody?

Antibody specificity for TDRD3 can be verified through several validation methods:

• Enhanced validation techniques using siRNA knockdown to evaluate decreased staining intensity

• Comparison of staining patterns using GFP-tagged TDRD3 fusion proteins

• Cross-validation using independent antibodies directed against different TDRD3 epitopes

• Western blot analysis confirming the expected molecular weight (~90 kDa for full-length TDRD3)

• Immunohistochemistry patterns consistent with known TDRD3 expression profiles across tissues

Researchers should choose validation methods appropriate for their specific experimental application and consider performing multiple validation approaches for critical experiments.

What are the recommended applications for TDRD3 antibodies?

TDRD3 antibodies have been validated for several experimental applications:

How should I optimize immunostaining protocols for detecting TDRD3 in different cellular compartments?

Given TDRD3's dual localization in nuclear and cytoplasmic compartments, optimization strategies should include:

• Fixation method selection: For nuclear TDRD3 detection, 4% paraformaldehyde provides good nuclear structure preservation; for cytoplasmic stress granule visualization, methanol fixation may better preserve cytoplasmic structures

• Permeabilization optimization: Triton X-100 (as used with ab251970) generally works well, but concentration may need adjustment (0.1-0.5%) depending on the cellular compartment of interest

• Blocking optimization: BSA (3-5%) with normal serum matching the secondary antibody host species

• Co-staining with compartment markers: Use nuclear markers (DAPI) and stress granule markers (G3BP1) to confirm specificity of localization

• Confocal microscopy: Recommended for accurate determination of subcellular localization

What are the best experimental designs for studying TDRD3's role in stress granule formation?

When investigating TDRD3's cytoplasmic function in stress granule assembly:

• Induction protocols: Compare multiple stress stimuli (arsenite, heat shock, viral infection) for stress granule formation

• Time-course analysis: Monitor TDRD3 recruitment to stress granules over time (5, 15, 30, 60 minutes post-stimulus)

• Colocalization studies: Co-stain with established stress granule markers (G3BP1, TIA-1)

• Knockdown validation: Use siRNA targeting TDRD3 to confirm antibody specificity and assess functional contribution to stress granule assembly

• Functional rescue: Complement with expression of siRNA-resistant TDRD3 constructs

TDRD3's role as an antiviral factor participating in stress granule assembly with G3BP1 makes this a particularly valuable research direction .

How can I utilize TDRD3 antibodies to investigate its interaction with dimethylarginine-containing proteins?

To study TDRD3's interactions with dimethylarginine-containing proteins:

• Co-immunoprecipitation: Use anti-TDRD3 antibodies for IP followed by immunoblotting for suspected interaction partners

• Proximity ligation assay (PLA): Combine TDRD3 antibody with antibodies against putative interaction partners to visualize and quantify protein interactions in situ

• ChIP-seq approaches: For studying histone interactions, specifically H3R17me2a and H4R3me2a modifications

• Peptide competition assays: Use differentially methylated peptides to compete for TDRD3 binding

• Domain-specific antibodies: Target the Tudor domain specifically when studying methylarginine interactions

The Tudor domain of TDRD3 is specifically involved in recognizing asymmetric dimethylation marks, making domain-specific approaches particularly informative .

What are the considerations when using TDRD3 antibodies for studying epigenetic regulation?

When investigating TDRD3's role as a coactivator that recognizes histone modifications:

• Chromatin fractionation: Optimize nuclear extraction protocols to preserve and enrich chromatin-bound TDRD3

• Sequential ChIP (ChIP-reChIP): Combine TDRD3 ChIP with histone modification ChIP to identify co-occupied regions

• Mutation analysis: Compare antibody binding to wild-type vs. mutant TDRD3 lacking methylarginine binding capacity

• Gene expression correlation: Correlate TDRD3 chromatin occupancy with transcriptional activation data

• Tissue-specific considerations: Account for differential expression patterns across cell types

TDRD3 specifically recognizes and binds asymmetric dimethylation on histone tails (H3R17me2a and H4R3me2a) associated with transcriptional activation, making it an important factor in epigenetic studies .

How can TDRD3 antibodies be used to differentiate between its nuclear and cytoplasmic functions?

To distinguish between TDRD3's compartment-specific functions:

• Subcellular fractionation: Separate nuclear, cytoplasmic, and chromatin fractions before immunoblotting

• Immunofluorescence with high-resolution microscopy: Confocal or super-resolution imaging to precisely localize TDRD3

• Truncation mutant analysis: Compare antibody reactivity with domain-specific constructs targeting nuclear vs. cytoplasmic functions

• Stress-response studies: Monitor TDRD3 translocation between compartments during stress responses

• Proximity-dependent labeling: BioID or APEX2 fusions with TDRD3 to identify compartment-specific interaction partners

Proper controls and validation are essential, as TDRD3's dual localization makes distinguishing compartment-specific functions challenging but crucial for understanding its diverse roles .

What are common issues with TDRD3 antibodies and how can they be addressed?

Researchers commonly encounter these challenges when working with TDRD3 antibodies:

• Background signal: Optimize blocking (5% BSA/normal serum), increase washing steps, and titrate antibody concentration

• Inconsistent detection: Ensure consistent fixation time and conditions; standardize cell culture conditions

• Epitope masking: If using paraformaldehyde fixation, test different antigen retrieval methods (heat-induced vs. enzymatic)

• Cross-reactivity: Validate specificity through knockdown experiments, particularly important when studying related Tudor domain proteins

• Batch-to-batch variation: Maintain detailed records of antibody lots and perform validation with each new lot

How do different fixation methods affect TDRD3 antibody performance?

Fixation method selection significantly impacts TDRD3 detection:

For highly sensitive applications, fixative choice should be experimentally determined for each specific TDRD3 antibody.

What controls should be included when using TDRD3 antibodies in experimental workflows?

Essential controls for TDRD3 antibody experiments include:

• Negative controls:

  • Primary antibody omission

  • Isotype control antibody at matching concentration

  • Pre-adsorption with immunizing peptide when available

  • TDRD3 knockdown or knockout samples

• Positive controls:

  • Cell lines with known TDRD3 expression (SK-MEL-30 has been validated)

  • Recombinant TDRD3 protein standards for Western blots

  • GFP-TDRD3 transfected cells for localization studies

• Specificity controls:

  • Multiple antibodies targeting different TDRD3 epitopes

  • Demonstration of expected molecular weight in Western blots

  • Expected subcellular localization pattern

These controls are particularly important given TDRD3's multiple functions and cellular localizations.

How can TDRD3 antibodies contribute to understanding its role in antiviral responses?

Recent research has identified TDRD3 as an antiviral factor involved in stress granule assembly . To investigate this function:

• Viral infection models: Use TDRD3 antibodies to monitor localization changes during viral infection

• Stress granule dynamics: Time-course studies of TDRD3 recruitment to stress granules using live-cell imaging combined with fixed-cell antibody validation

• Viral protein interactions: Investigate potential interactions between TDRD3 and viral proteins using co-immunoprecipitation

• TDRD3-G3BP1 complex formation: Study the interaction dynamics with G3BP1, a known stress granule component

• Knockout/knockdown phenotyping: Compare viral replication in TDRD3-deficient versus wildtype cells

This emerging area represents an important direction for TDRD3 research beyond its established roles in transcriptional regulation.

What approaches can be used to study potential TAB3-TDRD3 functional relationships?

Although TAB3 (TAK1-binding protein 3) and TDRD3 are distinct proteins, their related roles in signaling and potential functional overlap warrant investigation:

• Co-immunoprecipitation studies: Use antibodies against each protein to test for potential interactions

• Comparative localization: Use dual immunofluorescence to examine potential colocalization in response to stimuli

• Pathway analysis: Investigate whether TDRD3 participates in IL-1 or TNF signaling pathways where TAB3 functions

• Proteomic approaches: Use quantitative proteomics to identify potential shared interaction partners

• Functional redundancy testing: Examine whether TDRD3 can compensate for TAB3 deficiency in certain contexts

TAB3 associates with TAK1 through its C-terminal coiled-coil region and plays a role in IL-1 and TNF signaling pathways , while TDRD3 has distinct functions, making comparative studies potentially informative.

What are best practices for using TDRD3 antibodies in imaging-based phenotypic screens?

For high-throughput or high-content screening approaches:

• Optimization phases:

  • Establish robust staining protocols with minimal variability

  • Validate detection across multi-well plate formats

  • Determine optimal cell density and fixation timing

• Quantification parameters:

  • Nuclear vs. cytoplasmic intensity ratios

  • Stress granule number, size and intensity

  • Co-localization with functional markers

• Quality control measures:

  • Include positive/negative controls on each plate

  • Monitor batch effects across experimental runs

  • Implement automated image analysis pipelines with manual verification

• Validation strategies:

  • Confirm hits with orthogonal approaches

  • Validate with multiple TDRD3 antibodies

  • Correlate imaging data with biochemical measurements